Malignant Melanoma – Current Treatment – Current Treatment: Physician Insights – Malignant Melanoma (US)

Disease stage, primary tumor resectability, and BRAF mutation status are some of the key parameters influencing the treatment of malignant melanoma. For patients with BRAF mutations, BRAF/MEK inhibitor combination regimens such as Roche/Genentech’s Zelboraf + Cotellic ± Tecentriq, Novartis’s Tafinlar + Mekinist, and Pfizer’s Braftovi + Mektovi are key options. Immune checkpoint inhibitors, including Keytruda (Merck & Co.), Opdivo ± Yervoy (Bristol Myers Squibb), and Opdualag (Bristol Myers Squibb), along with Iovance Biotherapeutics’ Amtagvi, an autologous TIL therapy, can be used regardless of mutation status. Intratumoral treatments are limited to Amgen’s oncolytic viral therapy Imlygic, which is available only for patients with injectable lesions that cannot be surgically removed. This content evaluates the critical determinants influencing medical oncologists’ prescribing choices in the treatment of malignant melanoma.

QUESTIONS ANSWERED

• What are the current treatment practices in the adjuvant setting, and what factors influence the use of BRAF/MEK inhibitors versus anti-PD-1 therapy?
• What is the uptake of immune checkpoint inhibitors and BRAF/MEK inhibitors in the treatment of BRAF-mutation-positive malignant melanoma?
• How do drug-treatment rates vary across key patient populations according to stage of disease and line of therapy?
• Which drivers and constraints influence treatment decisions regarding key targeted therapies in the unresectable or metastatic setting?

Market covered: United States.

Primary research: Survey of 100 U.S. medical oncologists in December 2024.

Key drugs covered: Keytruda, Opdualag, Amtagvi, Opdivo ± Yervoy, Zelboraf, Cotellic, Tafinlar, Mekinist, Braftovi, Mektovi, Imlygic.

PRODUCT DESCRIPTION

Through survey data from U.S. physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:

• Understand the treatment landscape for a disease and how physicians make prescribing decisions.
• Evaluate the drivers and obstacles that influence treatment selection.
• Analyze your brand’s performance from the physician perspective to enhance or defend your competitive position.
• Create impactful messaging for physicians by identifying brand differentiators and understanding what motivates prescribing behaviors.